Nuevolution Appoints Henrik Simonsen
News Sep 17, 2015
Nuevolution A/S has announced that Henrik Simonsen has joined the company in the position as Chief Financial Officer. In his role, Mr. Simonsen will lead Nuevolution’s financial strategy including corporate finance and investor relations.
As member of Nuevolution’s Executive Management, he will play a key part in the strategy planning going forward. His most recent position was at SEB, where he was Sector Responsible for the Life Science arm of the Corporate Finance practice.
With Henrik Simonsen, Nuevolution appoints a seasoned professional, who has over 20 years of experience as an equity analysts covering Nordic, European and US life science companies as well as a number of years of corporate finance experience including several biotech IPO’s in Scandinavia.
“The appointment of Henrik Simonsen, to take charge of Nuevolution’s financial strategy and investor relations, represents an important step for Nuevolution in realization of our ambitious strategy of establishing a broad portfolio of clinical and pre-clinical programs within oncology, immunology and immuno-oncology.” said Alex Gouliaev, CEO of Nuevolution A/S and continued “Our programs addresses diseases with significant unmet need, and should therefore be developed as rapidly as possible. With Henrik’s strong corporate finance experience and investor network, we are confident that he will play a key role in helping secure future financing needed in realization of these important goals.”
“I am thrilled to be joining Nuevolution, which has developed the state-of-the art drug discovery platform, Chemetics, collaborates with leading drug companies and is building a promising pipeline in oncology, immuno-oncology and inflammation”, says Henrik Simonsen.
Most recently, Henrik served as Director and Sector Responsible for Life Science within Corporate Finance at SEB, where he was leading a number of Initial Public Offerings, venture capital raising initiatives as well as acting as an advisor to the executive management of several pharmaceutical and biotech companies.
Prior to SEB Corporate Finance, Henrik was Senior Equity Analyst at SEB and at Nordea Securities. Henrik obtained his Master of Science in Economics degree from the University of Copenhagen.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE